The Phase 3 data of donanemab, a potential treatment for Alzheimer's disease, has been announced by the Alzheimer's Association. The data, presented at the Alzheimer's Association International Conference® (AAIC®) 2023 by Eli Lilly and Company, showcases promising advancements in Alzheimer's research and treatment.   In the TRAILBLAZER-ALZ 2 clinical trial, donanemab demonstrated its ability..
ke-size="size16">Virios Therapeutics, Inc. (Nasdaq: VIRI), a biotechnology company focused on developing antiviral therapies for chronic diseases, has announced encouraging findings from a study demonstrating the effectiveness of a combination treatment in improving multiple Long-COVID symptoms. The study specifically targeted female patients diagnosed with Long-COVID illness, also known as Post..
소개 Searx는 개인 정보 보호와 사용자의 검색 자유를 중요시하는 오픈 소스 메타 검색 엔진입니다. 이 블로그에서는 시스템 엔지니어와 시니어 개발자의 관점에서 Searx에 대해 살펴보겠습니다. Searx는 사용자들이 자체 서버에서 검색 엔진을 호스팅 할 수 있어 웹 검색 결과의 개인화를 피하고, 추적을 피할 수 있는 장점이 있습니다. 또한 오픈 소스 프로젝트로서, 개발자들은 소스 코드를 확인하고 기여하여 프로젝트를 발전시킬 수 있습니다. 장점 개인 정보 보호 강화: Searx는 사용자의 검색 활동을 추적하지 않기 때문에 개인 정보 보호를 보장합니다. 중앙 서버가 개입하지 않고 사용자가 직접 검색을 수행하기 때문에, 사용자의 검색 쿼리와 기록이 수집되지 않습니다. - 사용자 정의 가능: Searx를 자체..
Neural Therapeutics Inc. (Neural), a company specializing in the discovery and development of ethnobotanical drugs, has successfully completed its rights offering. The offering came to an end on July 7, 2023, resulting in the issuance of 5,595,992 common shares at a price of $0.03 per share. This generated a total of approximately $167,880 in gross proceeds for Neural. The funds raised from the ..
CEL-SCI Corporation recently had a productive meeting with the U.S. Food and Drug Administration (FDA) regarding the approval of Multikine for head and neck cancer treatment. The FDA recognizes the urgent need for better therapies in this field and is willing to collaborate with CEL-SCI to demonstrate the effectiveness of Multikine as a potential treatment option. Additionally, CEL-SCI is active..
ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd., have responded to the European Society of Hypertension's (ESH) updated guidelines for the management of arterial hypertension. The ESH guidelines now endorse renal denervation as a treatment option for patients with resistant or uncontrolled hypertension despite medication use. ReCor Medical has conducted clinical tria..
size16">Asensus Surgical, formerly known as TransEnterix Inc., is revolutionizing surgery through digitization with its development of the LUNA Surgical System. This innovative system combines digital laparoscopy with robotic and instrument systems, incorporating machine vision and augmented intelligence to improve surgical outcomes and value-based healthcare. In an exciting announcement, Asensu..
Alphyn Biologics, a clinical-stage dermatology company, has announced promising interim findings from the Phase 2a trial of their topical treatment, AB-101a, for atopic dermatitis (AD) with secondary bacterial infection. The results indicate that AB-101a is effectively addressing all efficacy and safety measures across mild, moderate, and severe cases of AD. This therapeutic candidate is success..
